JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v8i12.8979ArticleAnalysis of Ophthalmology Drug Clinical Trial Institutions in China: Challenges and Opportunities Under the Registration Systemhttps://artdesignp.com/journal/JCNR/8/12/10.26689/jcnr.v8i12.8979XuRui,ZhangYurong,ZhaoYongxia,WangLi20248122024-12-09Objective: To analyze the status of ophthalmology drug clinical trial institutions in China following the implementation of the registration system and provide a reference for their development. Methods: An analysis was conducted using data from the Drug Clinical Trial Institution Registration Management Information Platform and the Drug Clinical Trial Registration and Information Publicity Platform of the National Medical Products Administration. The search period was up to April 19, 2024. Results: As of April 19, 2024, 314 ophthalmology-specific institutions were registered nationwide, comprising 274 comprehensive medical institutions and 40 specialized ophthalmology institutions, representing a 245% increase compared to the qualification certification phase. There were 965 major researchers in ophthalmology, accounting for 6.3% of the total number of researchers across all registered ophthalmology institutions. These institutions were predominantly located in economically developed areas such as Guangdong, Zhejiang, and Jiangsu Provinces, with the top five provinces and cities comprising 39.8% of the total registered institutions. Beijing had the highest number of major researchers (126), with their distribution positively correlated with the geographic spread of registered institutions. Furthermore, as of April 19, 2024, there were 216 clinical drugs related to eye diseases, with the top three provinces conducting 77.8% of national clinical trial projects. The number of institutions was directly proportional to the volume of clinical trials conducted. Conclusion: The implementation of the registration system has facilitated the release of ophthalmic medical resources. However, regional disparities remain in the number of ophthalmology-specific institutions, the availability of major investigators, and the distribution of clinical trial projects.

Xu T, Wang B, Liu H, et al., 2020, Prevalence and Causes of Vision Loss in China from 1990 to 2019: Findings from the Global Burden of Disease Study 2019. Lancet Public Health, 5(12): e682–e691. https://doi.org/10.1016/S2468-2667(20)30254-1

Hu J, Wang B, Dong W, 2020, Analysis of the Changing Trend of the Burden of Major Eye Diseases in China from 1990 to 2015. Medical Recapitulate, 26(1): 159–163 + 168.

Yao C, 2018, Clinical Trial in China: The Status and Challenge of Data Management and Statistical Analysis. J Evid Based Med, 11(1): 3–6. doi: 10.1111/jebm.12295

Zhang X, Chen X, Chen Q, et al., 2020, Opportunities and Challenges Faced by Ophthalmic Clinical Research in China. Eye Science, 35(5): 289–295.

General Office of the CPC Central Committee and General Office of the State Council, 2017, Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drugs and Medical Devices.

National Medical Products Administration, National Health Commission, 2019, Announcement on Issuing the Provisions on the Administration of Drug Clinical Trial Institutions (No. 101 of 2019).

Shi Z, Huo L, Zhou Y, et al., 2023, Analysis of Newly Filed Drug Clinical Trial Institutions in China and the Development of Their Clinical Trials. China Food and Drug Supervision, 2023(3): 50–57.

Zhang Y, Li J, Li M, et al., 2023, Analysis of the Current Situation of Drug Clinical Trial Institutions for Stomatology in China Under the Filing System. Chinese Journal of New Drugs and Clinical Remedies, 42(10): 651–655.

Fang H, Fan Q, Wang X, et al., 2021, Analysis of the Filing Status of Drug Clinical Trial Institutions in China. The Chinese Journal of Clinical Pharmacology, 37(4): 458–460.

You Y, Gao F, Xu X, et al., 2023, Analysis of the Current Situation of Drug Clinical Trial Institutions in China After the Filing System. Chinese Journal of New Drugs and Clinical Remedies, 42(3): 170–174.

Yang Z, Tang Y, Du Y, et al., 2021, An Overview of the Development of Clinical Trials of New Traditional Chinese Medicines in China. Chinese Journal of New Drugs and Clinical Remedies, 46(7): 1691–1695.

Yang Q, Liu L, Zhao Z, et al., 2023, Current Status and Analysis of the Filing of Drug Clinical Trial Institutions for Respiratory Diseases in China. Chinese Journal of Hospital Pharmacy, 42(3): 170–174.

Hu J, Xin C, Zhang L, et al., 2023, Analysis of the Implementation Status of Drug Clinical Trials for Product Registration and Marketing in Ophthalmology in China. Ophthalmology, 32(2): 98–102.

Liao R, Liang X, Zhang X, et al., 2022, Analysis of the Development Trend of New Drug Clinical Trials in Ophthalmology in China. Eye Science, 37(5): 401–407.

Tan Q, Qiu P, Li G, et al., 2023, Investigation and Analysis of the Current Quality Management Status of Drug Clinical Trial Institutions. Herald of Medicine, 42(12): 1884–1889.